A comparison of cancer stem cell markers and nonclassical major histocompatibility complex antigens in colorectal tumor and noncancerous tissues

Simple item page
dc.contributor.authorÖzgül Özdemir R.B.
dc.contributor.authorÖzdemir A.T.
dc.contributor.authorOltulu F.
dc.contributor.authorKurt K.
dc.contributor.authorYiğittürk G.
dc.contributor.authorKırmaz C.
dc.date.accessioned2024-07-22T08:11:26Z
dc.date.available2024-07-22T08:11:26Z
dc.date.issued2016
dc.description.abstractColorectal carcinoma (CRC) is one of the most fatal types of cancer in both women and men, and, unfortunately, patients are often diagnosed at an advanced stage. Cancer stem cells (CSCs) are associated with poor prognosis, metastasis, and recurrence, as well as chemotherapy and radiotherapy resistance. Therefore, different treatment alternatives are needed to facilitate the elimination of CSCs. One such approach is immunotherapy; however, tumor cells can evade immune cells by alteration of the expression patterns of human leukocyte antigens (HLA). In this study, we immunohistochemically investigated the expression patterns of CSC-specific markers CD44, CD133, Nanog, and Oct3/4, and immunosuppressive molecules HLA-G and -E in advanced CRC tumor tissues and noncancerous colon biopsies. We found significantly increased CD44, Nanog, Oct3/4, HLA-G, and HLA-E expression in the CRC tumor tissues compared with the noncancerous colon biopsies. These findings suggest that some tumor cells may be CSC-like and that the increased expression of HLA-G and HLA-E may be considered as an immune-evasive adaptation. Therefore, the nonclassical major histocompatibility complex class Ib antigens HLA-G and HLA-E may be potential targets in the elimination of CRC-CSCs. However, more detailed studies are required to support our findings. © 2016 Elsevier Inc.
dc.identifier.DOI-ID10.1016/j.anndiagpath.2016.09.012
dc.identifier.issn10929134
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/15663
dc.language.isoEnglish
dc.publisherW.B. Saunders
dc.subjectAdult
dc.subjectAged
dc.subjectAntigens, CD44
dc.subjectBiomarkers, Tumor
dc.subjectCell Line, Tumor
dc.subjectColorectal Neoplasms
dc.subjectFemale
dc.subjectHumans
dc.subjectMajor Histocompatibility Complex
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectNeoplastic Stem Cells
dc.subjectRecurrence
dc.subjectCD133 antigen
dc.subjectHermes antigen
dc.subjectHLA E antigen
dc.subjectHLA G antigen
dc.subjectoctamer transcription factor 4
dc.subjecttranscription factor NANOG
dc.subjectCD44 protein, human
dc.subjectHermes antigen
dc.subjecttumor marker
dc.subjectadult
dc.subjectadvanced cancer
dc.subjectantigen expression
dc.subjectArticle
dc.subjectcancer immunotherapy
dc.subjectcancer staging
dc.subjectcancer stem cell
dc.subjectclinical article
dc.subjectcolon biopsy
dc.subjectcolorectal cancer cell line
dc.subjectcolorectal carcinoma
dc.subjectcontrolled study
dc.subjectfemale
dc.subjecthistopathology
dc.subjecthuman
dc.subjecthuman cell
dc.subjecthuman tissue
dc.subjectimmunocompetent cell
dc.subjectimmunohistochemistry
dc.subjectlymph node metastasis
dc.subjectmale
dc.subjectmiddle aged
dc.subjectpriority journal
dc.subjecttumor escape
dc.subjectaged
dc.subjectcancer stem cell
dc.subjectColorectal Neoplasms
dc.subjectcomparative study
dc.subjectcytology
dc.subjectimmunology
dc.subjectmajor histocompatibility complex
dc.subjectmetabolism
dc.subjectpathology
dc.subjectrecurrent disease
dc.subjecttumor cell line
dc.titleA comparison of cancer stem cell markers and nonclassical major histocompatibility complex antigens in colorectal tumor and noncancerous tissues
dc.typeArticle

Files

Collections

Scopus Koleksiyonu